Piromelatine 20 mg in Participants With Mild Dementia Due to Alzheimer's Disease
Status:
Not yet recruiting
Trial end date:
2025-06-01
Target enrollment:
Participant gender:
Summary
Randomized efficacy and safety study of piromelatine 20 mg versus placebo in participants
with mild dementia due to Alzheimer's disease (AD) who are 2:107,510,000-107,540,000
polymorphism non-carriers with the primary objective to compare the effect of piromelatine to
that of placebo on the AD Assessment Scale cognitive subscale (ADAS-cog14) at Week 26 of
double-blind treatment.